6876 Stock Overview
Engages in the research and development of drugs for cancer patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
LAUNXP Biomedical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$17.20 |
| 52 Week High | NT$30.35 |
| 52 Week Low | NT$14.70 |
| Beta | 0 |
| 11 Month Change | 1.18% |
| 3 Month Change | -4.44% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -23.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6876 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 0.9% | 1.4% | 0.8% |
| 1Y | n/a | 7.5% | 30.3% |
Return vs Industry: Insufficient data to determine how 6876 performed against the TW Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 6876 performed against the TW Market.
Price Volatility
| 6876 volatility | |
|---|---|
| 6876 Average Weekly Movement | 8.0% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6876's share price has been volatile over the past 3 months compared to the TW market.
Volatility Over Time: 6876's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | n/a | www.launxp.com |
LAUNXP Biomedical Co., Ltd engages in the research and development of drugs for cancer patients. It develops various drugs, which are in preclinical stage, including LXP5948 for non-small cell lung cancer and Alzheimer's disease; LXP5268 for triple negative breast cancer; LXP5101 for pancreatic cancer; LXP1788 for gastrointestinal cancer; and Virus-like particles for cancer and genetic defect treatment. The company was founded in 2015 and is based in Taichung, Taiwan.
LAUNXP Biomedical Co., Ltd Fundamentals Summary
| 6876 fundamental statistics | |
|---|---|
| Market cap | NT$548.82m |
| Earnings (TTM) | NT$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6876 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6876 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$0 |
| Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 6876 perform over the long term?
See historical performance and comparison